Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
Demand normalisation post the second wave contributed to the steady growth
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
The company expects revenue growth of 10-15 per cent in the US
The data should be submitted by August 12th 2021
Price band in the range of Rs 933 to Rs 954
India business is growing as per projections; whereas US business will bounce back soon.
Subscribe To Our Newsletter & Stay Updated
